
    
      Each cycle will last for 4 weeks. Sorafenib and trametinib will be administered orally on
      continuous basis. During the first cycle sorafenib will be started on day 1 and trametinib on
      day 8 to improve tolerance. Participants will get restaging scans every 2 cycles.
      Participants will continue to receive treatment if they have a stable disease or a better
      response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1.
    
  